# Foresite Capital Opportunity Management V, LLC

> Institutional holdings reported to the SEC as of Q3 2022 on Form 13F. CIK 1792207. Source: https://holderbook.com/funds/1792207-foresite-capital-opportunity-management-v-llc/

- Reported value: $33.3M
- Positions: 9
- Weight of the ten largest: 100.0%
- Filed: 2022-11-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| PARDES BIOSCIENCES INC | [PRDS](https://holderbook.com/stocks/PRDS/) | $9.7M | 5,227,307 | 29.0% | 4 |
| THESEUS PHARMACEUTICALS INC | [THRX](https://holderbook.com/stocks/THRX/) | $5.6M | 959,275 | 16.7% | 4 |
| GEMINI THERAPEUTICS INC | [GMTX](https://holderbook.com/stocks/GMTX/) | $4.0M | 2,435,125 | 12.0% | 4 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $3.5M | 1,554,250 | 10.6% | 4 |
| KINNATE BIOPHARMA INC | [KNTE](https://holderbook.com/stocks/KNTE/) | $3.5M | 291,667 | 10.5% | 4 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $2.4M | 170,000 | 7.3% | 4 |
| QUANTUM SI INC | [QSI](https://holderbook.com/stocks/QSI/) | $1.7M | 633,626 | 5.2% | 4 |
| HIMS & HERS HEALTH INC | [HIMS](https://holderbook.com/stocks/HIMS/) | $1.7M | 306,431 | 5.1% | 2 |
| ENANTA PHARMACEUTICALS INC | [ENTA](https://holderbook.com/stocks/ENTA/) | $1.2M | 22,750 | 3.5% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q3 2022 | -16.1% | -5.3% | -10.7% | 100% |
| Q2 2022 | -39.9% | -16.5% | -23.5% | 100% |
| Q1 2022 | -49.0% | -4.9% | -44.1% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q3 2022 | $33.3M | 9 |
| Q2 2022 | $39.7M | 9 |
| Q1 2022 | $71.4M | 10 |
| Q4 2021 | $149.2M | 9 |